Advances in Preclinical Investigation of Prostate Cancer Gene Therapy

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2007 Apr 26

PMID 17457317

Citations 10

Authors

Marxa L Figueiredo

Chinghai Kao

Lily Wu

Affiliations

Soon will be listed here.

Abstract

Treating recurrent prostate cancer poses a great challenge to clinicians. Research efforts in the last decade have shown that adenoviral vector-based gene therapy is a promising approach that could expand the arsenal against prostate cancer. This maturing field is at the stage of being able to translate many preclinical discoveries into clinical practices. At this juncture, it is important to highlight the promising strategies including prostate-targeted gene expression, the use of oncolytic vectors, therapy coupled to reporter gene imaging, and combined treatment modalities. In fact, the early stages of clinical investigation employing combined, multimodal gene therapy focused on loco-regional tumor eradication and showed promising results. Clinicians and scientists should seize the momentum of progress to push forward to improve the therapeutic outcome for the patients.

Citing Articles

Oncolytic adenovirus-mediated therapy for prostate cancer.

Sweeney K, Hallden G Oncolytic Virother. 2016; 5:45-57.

PMID: 27579296 PMC: 4996256. DOI: 10.2147/OV.S63047.

AEG-1 promoter-mediated imaging of prostate cancer.

Bhatnagar A, Wang Y, Mease R, Gabrielson M, Sysa P, Minn I Cancer Res. 2014; 74(20):5772-81.

PMID: 25145668 PMC: 4234089. DOI: 10.1158/0008-5472.CAN-14-0018.

Nucleic acid-based approaches to STAT inhibition.

Sen M, Grandis J JAKSTAT. 2013; 1(4):285-91.

PMID: 24058785 PMC: 3670286. DOI: 10.4161/jkst.22312.

Interleukin-27 gene delivery for modifying malignant interactions between prostate tumor and bone.

Zolochevska O, Ellis J, Parelkar S, Chan-Seng D, Emrick T, Wei J Hum Gene Ther. 2013; 24(12):970-81.

PMID: 24028178 PMC: 3868392. DOI: 10.1089/hum.2013.091.

Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer.

Jiang Z, Sato M, Wei L, Kao C, Wu L Cancer Res. 2011; 71(19):6250-60.

PMID: 21933883 PMC: 3185197. DOI: 10.1158/0008-5472.CAN-11-1520.

References

Cho J, Shen D, Yang W, Williams B, Buckwalter T, La Perle K . In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas. Gene Ther. 2002; 9(17):1139-45. DOI: 10.1038/sj.gt.3301787. View

Kokoris M, Black M . Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity. Protein Sci. 2002; 11(9):2267-72. PMC: 2373606. DOI: 10.1110/ps.2460102. View

Chung J . Sodium iodide symporter: its role in nuclear medicine. J Nucl Med. 2002; 43(9):1188-200. View

Yousef G, Diamandis E . Expanded human tissue kallikrein family--a novel panel of cancer biomarkers. Tumour Biol. 2002; 23(3):185-92. DOI: 10.1159/000064027. View

Lee S, Kim H, Yu R, Lee K, Gardner T, Jung C . Novel prostate-specific promoter derived from PSA and PSMA enhancers. Mol Ther. 2002; 6(3):415-21. DOI: 10.1006/mthe.2002.0682. View

Freytag S, Paielli D, Wing M, Rogulski K, Brown S, Kolozsvary A . Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol Phys. 2002; 54(3):873-85. DOI: 10.1016/s0360-3016(02)03005-5. View

Groot-Wassink T, Aboagye E, Glaser M, Lemoine N, Vassaux G . Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther. 2002; 13(14):1723-35. DOI: 10.1089/104303402760293565. View

Ikegami S, Tadakuma T, Suzuki S, Yoshimura I, Asano T, Hayakawa M . Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre Recombinase/LoxP system for prostate cancer cells under androgen ablation condition. Jpn J Cancer Res. 2002; 93(10):1154-63. PMC: 5926883. DOI: 10.1111/j.1349-7006.2002.tb01218.x. View

Ng C, Zisman A, Bonavida B . Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate. 2002; 53(4):286-99. DOI: 10.1002/pros.10155. View

10.

Edwards S, Dix B, Myers C, Dobson-Le D, Huschtscha L, Hibma M . Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J Virol. 2002; 76(24):12483-90. PMC: 136704. DOI: 10.1128/jvi.76.24.12483-12490.2002. View

11.

Yoshimura I, Ikegami S, Suzuki S, Tadakuma T, Hayakawa M . Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system. J Urol. 2002; 168(6):2659-64. DOI: 10.1016/S0022-5347(05)64239-5. View

12.

Zhang Y, Yu J, Unni E, Shao T, Nan B, Snabboon T . Monogene and polygene therapy for the treatment of experimental prostate cancers by use of apoptotic genes bax and bad driven by the prostate-specific promoter ARR(2)PB. Hum Gene Ther. 2002; 13(17):2051-64. DOI: 10.1089/10430340260395901. View

13.

Block A, Milasinovic D, Mueller J, Schaefer P, Schaefer H, Greten H . Amplified Muc1-specific gene expression in colon cancer cells utilizing a binary system in adenoviral vectors. Anticancer Res. 2003; 22(6A):3285-92. View

14.

Hecht J, Bedford R, Abbruzzese J, Lahoti S, Reid T, Soetikno R . A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res. 2003; 9(2):555-61. View

15.

Satoh T, Timme T, Saika T, Ebara S, Yang G, Wang J . Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum Gene Ther. 2003; 14(2):91-101. DOI: 10.1089/104303403321070793. View

16.

Massoud T, Gambhir S . Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003; 17(5):545-80. DOI: 10.1101/gad.1047403. View

17.

Kubo H, Gardner T, Wada Y, Koeneman K, Gotoh A, Yang L . Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther. 2003; 14(3):227-41. DOI: 10.1089/10430340360535788. View

18.

Furuhata S, Ide H, Miura Y, Yoshida T, Aoki K . Development of a prostate-specific promoter for gene therapy against androgen-independent prostate cancer. Mol Ther. 2003; 7(3):366-74. DOI: 10.1016/s1525-0016(02)00059-x. View

19.

Sauthoff H, Hu J, Maca C, Goldman M, Heitner S, Yee H . Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum Gene Ther. 2003; 14(5):425-33. DOI: 10.1089/104303403321467199. View

20.

Kaczmarczyk S, Green J . Induction of cre recombinase activity using modified androgen receptor ligand binding domains: a sensitive assay for ligand-receptor interactions. Nucleic Acids Res. 2003; 31(15):e86. PMC: 169976. DOI: 10.1093/nar/gng087. View